Revision per component name

Cemented primary THA – overall revision
Uncemented primary THA – overall revsion
Cemented primary THA – major revision
Uncemented primary THA – major revision
Bone cement THA

Hip » Survival » Revision per component name » Cemented primary THA – overall revision

TABLE Cumulative revision percentages of cemented primary total hip arthroplasties by prosthesis component combination of patients who underwent a THA for osteoarthritis in the Netherlands in 2007-2022 (n=89,014)

					Type of revision (n)					Cumulative revision percentage (95% CI)
Femur component	Acetabulum component	Total primary THAs (n)	Median (IQR) age (yr)	Total revision arthroplasties (n)	Total hip (complete revision)	Only femur component	Only acetabulum component	Only femoral head/inlay	Missing/ unknown	1yr	3yr	5yr	7yr	10yr	14yr
All cemented THAs for osteoarthritis		89,014	76 (71-81)	2,607	512	269	1,056	723	47	1.3 (1.2-1.4)	2.1 (2.0-2.2)	2.6 (2.5-2.7)	3.0 (2.9-3.1)	3.7 (3.6-3.9)	4.7 (4.4-4.9)
Lubinus SPII	IP Cup	15,008	77 (72-81)	395	61	48	176	104	6	1.1 (1.0-1.3)	2.0 (1.7-2.2)	2.5 (2.2-2.8)	2.8 (2.5-3.1)	3.2 (2.8-3.5)	4.1 (3.5-4.6)
Original ME Muller	Muller low profile Durasul	9,450	75 (70-80)	258	30	5	65	155	3	1.8 (1.5-2.1)	2.4 (2.0-2.7)	2.8 (2.4-3.2)	3.1 (2.7-3.5)	3.6 (3.1-4.1)	4.0 (3.3-4.6)
Lubinus SPII	FAL Cup	6,450	75 (70-80)	213	49	13	77	69	5	1.9 (1.6-2.2)	2.6 (2.2-3.0)	3.2 (2.7-3.6)	3.8 (3.3-4.3)	4.5 (3.8-5.2)	5.5 (4.4-6.5)
Original ME Muller	Muller low profile	6,443	77 (73-81)	188	24	2	113	43	6	1.4 (1.1-1.7)	2.3 (2.0-2.7)	2.7 (2.3-3.1)	3.1 (2.7-3.6)	3.2 (2.7-3.6)	3.6 (3.0-4.2)
Exeter	Exeter Rimfit X3	5,098	76 (69-80)	114	28	25	24	37	0	1.3 (1.0-1.6)	1.9 (1.5-2.3)	2.3 (1.9-2.8)	2.5 (2.0-3.0)	3.2 (2.4-3.9)	n.a.
Spectron EF	Reflection All Poly XLPE	4,976	77 (73-82)	121	42	14	41	24	0	0.7 (0.4-0.9)	1.4 (1.1-1.8)	1.9 (1.5-2.2)	2.5 (2.1-3.0)	2.9 (2.4-3.5)	3.1 (2.6-3.7)
Stanmore	Stanmore	3,381	75 (70-80)	77	25	2	41	6	3	0.7 (0.4-1.0)	1.5 (1.0-1.9)	1.9 (1.4-2.3)	2.1 (1.6-2.6)	2.5 (1.9-3.1)	3.1 (2.2-4.0)
Exeter	Exeter Contemporary Hooded	2,827*	77 (72-81)	101	23	23	38	14	3	1.2 (0.8-1.6)	1.7 (1.2-2.2)	2.3 (1.7-2.9)	2.9 (2.3-3.6)	4.3 (3.4-5.2)	5.1 (3.9-6.2)
Lubinus SPII	SHP	2,506*	75 (71-80)	48	9	3	35	1	0	0.2 (0.0-0.4)	0.7 (0.3-1.0)	1.0 (0.6-1.3)	1.7 (1.2-2.2)	2.0 (1.4-2.6)	2.5 (1.6-3.4)
Exeter	Exeter	2,447*	73 (68-79)	150	24	14	77	30	5	2.8 (2.1-3.4)	3.6 (2.8-4.3)	4.1 (3.3-4.9)	4.9 (4.1-5.8)	6.3 (5.2-7.3)	7.2 (6.0-8.4)
Exeter	Exeter Contemporary Flanged	2,439	75 (67-80)	79	17	9	42	9	2	0.8 (0.4-1.1)	1.4 (0.9-1.9)	2.0 (1.4-2.6)	2.3 (1.7-2.9)	3.2 (2.4-4.0)	5.2 (3.8-6.6)
Stanmore	SHP	2,097*	75 (71-79)	116	39	5	60	10	2	1.6 (1.0-2.1)	3.1 (2.3-3.8)	4.0 (3.1-4.9)	4.7 (3.7-5.6)	5.6 (4.5-6.7)	7.7 (6.1-9.3)
CCA stem	CCB cup Low Profile	1,788	77 (73-80)	60	9	6	15	29	1	2.0 (1.4-2.7)	2.7 (1.9-3.4)	3.0 (2.1-3.8)	3.3 (2.4-4.1)	4.3 (3.0-5.5)	5.5 (3.3-7.6)
Original ME Muller	Avantage Cemented	1,530	77 (71-82)	55	0	1	5	45	1	3.1 (2.2-4.0)	3.7 (2.7-4.8)	4.9 (3.3-6.5)	5.5 (3.6-7.4)	n.a.	n.a.
C-Stem AMT	Marathon	1,485	79 (74-83)	19	3	3	0	16	0	1.1 (0.6-1.6)	1.4 (0.8-2.1)	1.4 (0.8-2.1)	n.a.	n.a.	n.a.
Stanmore	Exceed ABT Cemented	1,338	76 (71-81)	28	6	1	11	10	0	1.1 (0.5-1.6)	1.6 (0.9-2.2)	2.3 (1.4-3.3)	3.3 (1.8-4.8)	n.a.	n.a.
Lubinus SPII	IP Cup X-Linked	1,321	78 (73-82)	31	7	3	8	13	0	1.4 (0.8-2.1)	2.3 (1.4-3.2)	3.1 (2.0-4.2)	3.1 (2.0-4.2)	n.a.	n.a.
Twinsys stem Cemented	CCB cup Low Profile	1,158	80 (76-83)	16	1	3	6	5	1	0.8 (0.3-1.4)	1.4 (0.6-2.1)	1.7 (0.8-2.6)	2 .0(1.0-3.0)	2.0 (1.0-3.0)	n.a.
Stanmore	All Poly Arcom Cup	1,056*	74 (69-79)	22	3	4	14	0	1	0.3 (0.0-0.6)	1.3 (0.6-2.0)	1.7 (0.9-2.5)	1.8 (1.0-2.7)	2.7 (1.5-3.9)	n.a.
Lubinus SPII	Avantage Cemented	930	78 (72-83)	34	6	1	4	23	0	3.1 (2.0-4.2)	3.4 (2.2-4.6)	4.4 (2.8-6.1)	5.2 (3.0-7.3)	n.a.	n.a.
Stanmore	Muller	879	76 (71-81)	12	3	2	6	1	0	0.7 (0.1-1.2)	1.3 (0.5-2.0)	1.3 (0.5-2.0)	1.3 (0.5-2.0)	1.6 (0.6-2.6)	n.a.
Spectron EF	Muller cup	831*	77 (72-81)	12	3	2	4	3	0	0.4 (0.0-0.8)	0.7 (0.1-1.3)	1.0 (0.3-1.6)	1.1 (0.4-1.8)	1.4 (0.6-2.1)	1.5 (0.7-2.4)
Spectron EF	Reflection All Poly	617*	77 (74-82)	50	11	0	35	4	0	0.8 (0.1-1.5)	1.8 (0.7-2.9)	2.7 (1.4-4.0)	3.3 (1.8-4.7)	6.6 (4.5-8.8)	10.5 (7.7-13.3)
Spectron EF	Muller low profile Durasul	503*	78 (74-83)	13	5	0	2	6	0	0.8 (0.0-1.6)	1.6 (0.5-2.8)	2.1 (0.8-3.4)	3.4 (1.5-5.3)	n.a.	n.a.
MS30	Muller low profile	497*	78 (74-82)	17	0	8	9	0	0	0.8 (0.0-1.6)	1.7 (0.5-2.8)	2.3 (1.0-3.7)	2.9 (1.3-4.5)	4.8 (2.4-7.1)	n.a.
Lubinus SPII	FAL Cup X-Linked	442	78 (74-81)	5	0	1	3	1	0	0.5 (0.0-1.2)	1.3 (0.0-2.7)	2.5 (0.0-5.0)	n.a.	n.a.	n.a.
Exeter	Avantage Cemented	436	74 (66-81)	9	3	2	0	4	0	1.4 (0.3-2.6)	2.2 (0.7-3.8)	2.8 (0.9-4.7)	2.8 (0.9-4.7)	n.a.	n.a.
Stanmore	Apollo	381*	75 (70-79)	6	3	1	1	0	1	0.3 (0.0-0.8)	0.8 (0.0-1.7)	1.4 (0.2-2.6)	1.4 (0.2-2.6)	1.7 (0.4-3.1)	n.a.
Stanmore	Avantage Cemented	369	79 (74-84)	11	0	1	0	10	0	2.2 (0.7-3.7)	3.0 (1.3-4.8)	3.0 (1.3-4.8)	n.a.	n.a.	n.a.
GHE-huftstiel	Huftpfanne	273*	75 (71-80)	23	5	3	15	0	0	0.4 (0.0-1.1)	1.5 (0.0-3.0)	2.7 (0.7-4.7)	4.4 (1.8-6.9)	7.2 (3.9-10.6)	n.a.
Charnley Modular	Marathon	255*	71 (65-79)	10	3	5	2	0	0	0.4 (0.0-1.2)	1.2 (0.0-2.6)	1.6 (0.0-3.2)	4.0 (1.4-6.5)	4.5 (1.8-7.3)	n.a.

* Denotes prosthesis combinations with no reported use in primary THAs in 2022.
Please note: n.a. if <50 cases were at risk; THA: total hip arthroplasty; RA: revision arthroplasty; CI: confidence interval; IQR: interquartile range.

Only combinations with over 250 procedures have been listed.
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure, femoral head size and articulation of the prosthesis may have influenced the cumulative revision percentages.

Hip » Survival » Revision per component name » Uncemented primary THA – overall revision

TABLE Cumulative revision percentages of uncemented primary total hip arthroplasties by prosthesis component combination of patients who underwent a THA for osteoarthritis in the Netherlands in 2007-2022 (n=230,573)

					Type of revision (n)					Cumulative revision percentage (95% CI)
Femur component	Acetabulum component	Total primary THAs (n)	Median (IQR) age (yr)	Total RAs (n)	Total hip (complete revision)	Only femur component	Only acetabulum component	Only femoral head/inlay	Missing/ unknown	1yr	3yr	5yr	7yr	10yr	14yr
All uncemented THAs for osteoarthritis		230,573	68 (62-74)	8,232	1,349	2,880	2,155	1,709	139	1.5 (1.5-1.6)	2.5 (2.4-2.5)	3.1 (3.0-3.2)	3.7 (3.6-3.8)	4.6 (4.5-4.7)	5.9 (5.7-6.1)
Corail	Pinnacle	41,174	69 (63-75)	928	173	286	194	264	11	1.1 (1.0-1.2)	1.8 (1.6-1.9)	2.2 (2.1-2.4)	2.5 (2.4-2.7)	3.3 (3.1-3.6)	3.7 (3.3-4.0)
Taperloc Complete	Allofit	24,355	67 (61-73)	473	87	168	88	123	7	1.4 (1.3-1.6)	2.1 (1.9-2.2)	2.5 (2.3-2.7)	2.6 (2.3-2.8)	n.a.	n.a.
Alloclassic Zweymuller SL	Allofit	14,806	70 (64-77)	538	85	208	130	110	5	1.2 (1.0-1.4)	2.0 (1.8-2.2)	2.6 (2.4-2.9)	3.2 (2.9-3.5)	4.3 (3.9-4.6)	5.3 (4.7-5.8)
Polarstem	R3	12,311	70 (63-75)	267	26	87	36	116	2	1.8 (1.5-2.0)	2.3 (2.0-2.6)	2.8 (2.4-3.3)	3.0 (2.4-3.6)	n.a.	n.a.
CLS Spotorno	Allofit	11,557	64 (58-69)	537	54	203	153	109	18	2.6 (2.3-2.9)	3.7 (3.3-4.0)	4.2 (3.8-4.5)	4.7 (4.3-5.1)	5.3 (4.8-5.8)	6.0 (5.2-6.7)
Taperloc Complete	Exceed ABT	8,825	69 (63-75)	201	37	73	38	49	4	1.4 (1.2-1.7)	1.9 (1.6-2.2)	2.2 (1.9-2.5)	2.5 (2.1-2.8)	2.8 (2.4-3.3)	n.a.
Accolade	Trident	7,605	69 (62-76)	344	47	178	49	68	2	1.4 (1.1-1.7)	2.8 (2.5-3.2)	3.7 (3.3-4.1)	4.5 (4.0-5.0)	5.5 (4.9-6.2)	8.3 (6.3-10.4)
Mallory Head Stems	Mallory Head	6,019	65 (60-69)	228	28	23	101	70	6	1.4 (1.1-1.7)	2.3 (1.9-2.6)	2.7 (2.3-3.1)	3.2 (2.8-3.7)	3.8 (3.2-4.3)	4.9 (4.1-5.7)
Accolade II	Trident	5,021	69 (62-75)	94	15	36	12	29	2	1.7 (1.3-2.0)	2.3 (1.7-2.8)	2.5 (1.8-3.3)	4.3 (0.8-7.7)	n.a.	n.a.
Twinsys stem Cementless	RM Pressfit Vitamys cup	4,888	66 (60-72)	145	16	65	37	24	3	1.8 (1.4-2.2)	2.5 (2.0-2.9)	2.9 (2.3-3.4)	3.2 (2.6-3.8)	4.8 (3.8-5.8)	n.a.
Accolade	Trident Trinanium	4,539*	68 (62-74)	139	13	48	31	44	3	1.1 (0.8-1.4)	2.2 (1.8-2.6)	2.8 (2.3-3.3)	3.3 (2.7-3.8)	3.9 (3.1-4.6)	n.a.
Taperloc Hip system	Exceed ABT	3,893*	68 (62-75)	127	22	35	37	25	8	1.2 (0.8-1.5)	2.3 (1.8-2.8)	2.7 (2.2-3.2)	2.9 (2.4-3.5)	3.4 (2.8-4.0)	n.a.
SL Plus	Bicon Plus	3,777	70 (64-76)	274	40	138	75	18	3	1.7 (1.3-2.1)	4.0 (3.3-4.6)	5.4 (4.7-6.1)	6.4 (5.6-7.2)	7.6 (6.7-8.5)	8.8 (7.6-9.9)
Taperloc Hip system	Mallory Head	3,670*	67 (61-71)	137	26	38	49	23	1	1.5 (1.1-1.8)	2.6 (2.1-3.1)	2.9 (2.4-3.5)	3.4 (2.8-4.0)	3.7 (3.1-4.4)	4.7 (3.7-5.6)
Twinsys stem Cementless	RM Pressfit cup	3,402	73 (68-78)	131	18	61	25	26	1	2.5 (2.0-3.0)	3.1 (2.5-3.7)	3.4 (2.8-4.1)	3.9 (3.2-4.6)	4.6 (3.7-5.5)	n.a.
Taperloc Complete	Mallory Head	3,113	67 (61-72)	117	20	25	32	39	1	2.1 (1.6-2.6)	3.1 (2.5-3.7)	3.4 (2.7-4.0)	3.7 (3.0-4.4)	4.4 (3.4-5.4)	n.a.
Alloclassic offset	Allofit	2,966	71 (65-77)	89	19	35	16	16	3	1.4 (0.9-1.8)	2.0 (1.5-2.5)	2.6 (2.0-3.2)	2.9 (2.2-3.5)	3.8 (2.9-4.7)	4.5 (3.4-5.6)
Synergy	Reflection	2,930*	66 (60-72)	146	12	69	30	34	1	2.1 (1.6-2.6)	2.7 (2.1-3.3)	3.1 (2.5-3.7)	3.6 (2.9-4.3)	4.4 (3.6-5.2)	6.7 (5.4-8.0)
Alloclassic Zweymuller SL	Alloclassic Zweymuller CSF	2,903*	69 (63-75)	136	18	55	26	35	2	1.1 (0.7-1.5)	2.7 (2.1-3.2)	3.3 (2.6-3.9)	3.5 (2.8-4.2)	4.4 (3.6-5.1)	5.6 (4.6-6.6)
Taperloc Complete	G7 PPS	2,884	69 (63-75)	42	11	11	10	10	0	1.7 (1.1-2.2)	n.a.	n.a.	n.a.	n.a.	n.a.
M/L Taper	Allofit IT	2,437	71 (65-77)	81	10	32	28	10	1	2.2 (1.6-2.8)	3.2 (2.4-3.9)	3.6 (2.8-4.4)	3.9 (3.0-4.7)	4.1 (3.1-5.0)	n.a.
Corail AMT	Pinnacle	2,432	69 (61-74)	24	3	6	6	9	0	0.8 (0.4-1.1)	1.1 (0.6-1.5)	n.a.	n.a.	n.a.	n.a.
Avenir Muller	Allofit	2,245	68 (62-74)	28	3	12	3	10	0	1.2 (0.7-1.6)	1.5 (0.8-2.1)	1.7 (0.9-2.5)	2.2 (1.1-3.3)	2.2 (1.1-3.3)	n.a.
Synergy	R3	2,102	66 (60-72)	67	11	35	11	8	2	1.8 (1.2-2.4)	2.3 (1.7-2.9)	2.9 (2.1-3.6)	3.2 (2.4-4.0)	3.4 (2.6-4.3)	n.a.
Symax	Trident	2,073*	69 (63-75)	74	7	19	20	28	0	0.6 (0.3-0.9)	1.7 (1.1-2.2)	2.2 (1.5-2.8)	2.8 (2.0-3.5)	3.2 (2.4-4.0)	4.1 (3.1-5.0)
Fitmore	Allofit	1,946	67 (62-72)	27	7	9	2	8	1	1.2 (0.7-1.7)	1.7 (0.9-2.5)	n.a.	n.a.	n.a.	n.a.

TABLE Continued – Cumulative revision percentages of uncemented primary total hip arthroplasties by prosthesis component combination of patients who underwent a THA for osteoarthritis in the Netherlands in 2007-2022 (n=230,573)

					Type of revision (n)					Cumulative revision percentage (95% CI)
Femur component	Acetabulum component	Total primary THAs (n)	Median (IQR) age (yr)	Total RAs (n)	Total hip (complete revision)	Only femur component	Only acetabulum component	Only femoral head/inlay	Missing/ unknown	1yr	3yr	5yr	7yr	10yr	13yr
Anthology	R3	1,843	65 (59-69)	61	9	20	17	15	0	2.1 (1.4-2.7)	2.6 (1.9-3.4)	3.3 (2.4-4.1)	3.5 (2.6-4.3)	3.7 (2.7-4.6)	n.a.
Symax	Trident Tritanium	1,743*	67 (61-73)	92	11	41	26	13	1	2.3 (1.6-3.0)	3.6 (2.7-4.5)	4.0 (3.0-4.9)	4.8 (3.8-5.8)	5.4 (4.3-6.5)	n.a.
Mallory Head Stems	Exceed ABT	1,637*	65 (59-71)	38	3	16	17	2	0	0.7 (0.3-1.1)	1.6 (1.0-2.2)	1.7 (1.1-2.4)	2.1 (1.4-2.8)	2.4 (1.6-3.2)	n.a.
Omnifit HA	Trident	1,501*	63 (57-67)	148	19	71	24	30	4	3.1 (2.2-3.9)	4.5 (3.4-5.5)	6.3 (5.0-7.5)	7.7 (6.4-9.1)	9.5 (8.0-11.0)	10.8 (9.1-12.4)
M/L Taper	Continuum	1,472	68 (63-73)	30	3	20	4	3	0	1.6 (0.9-2.3)	2.2 (1.4-2.9)	2.3 (1.5-3.2)	2.3 (1.5-3.2)	n.a.	n.a.
Alloclassic Zweymuller SL	Continuum	1,246	71 (64-77)	36	7	14	4	10	1	1.6 (0.9-2.3)	2.2 (1.4-3.0)	2.6 (1.7-3.5)	2.9 (2.0-3.9)	3.4 (2.2-4.5)	n.a.
CLS Spotorno	RM Classic cup	1,178*	63 (58-68)	78	14	22	34	7	1	1.9 (1.1-2.6)	2.6 (1.7-3.6)	3.3 (2.3-4.4)	3.9 (2.8-5.0)	5.1 (3.8-6.3)	7.0 (5.5-8.6)
CLS Spotorno	Pinnacle	1,165*	67 (62-72)	59	8	22	13	16	0	1.3 (0.6-1.9)	2.3 (1.4-3.1)	2.8 (1.8-3.8)	3.5 (2.4-4.6)	4.9 (3.5-6.3)	n.a.
Summit Tapered	Pinnacle Gription	1,117	68 (62-74)	28	2	7	5	13	1	2.2 (1.3-3.0)	2.4 (1.5-3.3)	3.0 (1.7-4.4)	n.a.	n.a.	n.a.
SL Plus Mia	R3	1,109*	71 (65-77)	34	3	16	7	8	0	1.9 (1.1-2.7)	2.7 (1.8-3.7)	3.0 (2.0-4.1)	3.0 (2.0-4.1)	3.3 (2.2-4.4)	n.a.
SL Plus	Reflection	1,020*	67 (61-73)	43	6	14	14	9	0	1.8 (1.0-2.6)	3.3 (2.2-4.4)	3.8 (2.6-5.0)	4.3 (3.0-5.5)	4.4 (3.1-5.7)	n.a.
SL Plus	Hofer-Imhoff Lubrimet	978*	70 (64-76)	61	13	30	10	6	2	1.1 (0.5-1.8)	2.3 (1.3-3.2)	3.6 (2.4-4.7)	4.4 (3.1-5.8)	5.6 (4.1-7.1)	7.5 (5.6-9.4)
Alloclassic Zweymuller SL	Trilogy	967*	68 (63-75)	35	10	10	7	8	0	1.4 (0.6-2.1)	2.2 (1.3-3.1)	2.6 (1.6-3.6)	2.9 (1.9-4.0)	3.6 (2.4-4.8)	3.7 (2.5-4.9)
Polarstem	Reflection	927*	70 (64-76)	18	5	4	2	7	0	1.1 (0.4-1.7)	1.6 (0.8-2.4)	2.1 (1.1-3.0)	2.1 (1.1-3.0)	n.a.	n.a.
Accolade II	Trident Tritanium	904	68 (61-73)	20	2	7	3	8	0	2.6 (1.3-3.8)	3.3 (1.7-4.9)	n.a.	n.a.	n.a.	n.a.
Optimys stem	RM Pressfit Vitamys cup	896	62 (55-68)	17	2	9	3	2	1	1.8 (0.9-2.7)	2.1 (1.1-3.1)	2.1 (1.1-3.1)	2.1 (1.1-3.1)	n.a.	n.a.
Taperloc Complete	Continuum	814	68 (59-74)	18	5	7	1	5	0	2.0 (1.0-2.9)	2.3 (1.3-3.4)	n.a.	n.a.	n.a.	n.a.
SL Plus	EP-Fit Plus	790*	68 (63-75)	45	10	24	10	1	0	1.3 (0.5-2.1)	3.1 (1.9-4.3)	3.8 (2.4-5.1)	4.9 (3.3-6.4)	5.7 (4.0-7.3)	6.3 (4.5-8.0)
Alloclassic Zweymuller SL	Alloclassic Variall	778*	71 (64-77)	23	4	10	3	5	1	1.0 (0.3-1.7)	1.9 (1.0-2.9)	2.4 (1.3-3.4)	2.6 (1.5-3.8)	3.0 (1.7-4.2)	3.3 (1.9-4.7)
CLS Spotorno	Fitmore	758*	66 (61-71)	37	3	17	6	10	1	1.9 (0.9-2.8)	2.4 (1.3-3.5)	2.6 (1.5-3.8)	3.3 (2.0-4.6)	4.3 (2.9-5.8)	5.3 (3.6-7.0)
DB10	Spidercup	755*	71 (64-77)	40	2	20	10	7	1	1.5 (0.6-2.3)	2.3 (1.2-3.3)	2.9 (1.6-4.1)	3.7 (2.4-5.1)	4.8 (3.2-6.4)	6.6 (4.5-8.8)
CLS Spotorno	Morscher	712*	73 (68-78)	37	6	19	12	0	0	1.3 (0.4-2.1)	2.6 (1.4-3.7)	3.2 (1.9-4.5)	4.2 (2.7-5.7)	5.6 (3.8-7.5)	n.a.
CLS Spotorno	RM Pressfit cup	625*	66 (60-71)	54	5	21	19	5	4	3.1 (1.7-4.4)	4.4 (2.8-6.0)	5.7 (3.9-7.5)	6.6 (4.6-8.6)	7.9 (5.7-10.1)	9.8 (7.3-12.3)
Corail	Pinnacle Gription	599	71 (64-77)	5	0	4	1	0	0	0.6 (0.0-1.2)	n.a.	n.a.	n.a.	n.a.	n.a.
CBH stem	RM Pressfit Vitamys cup	593*	65 (60-70)	24	8	7	7	2	0	1.0 (0.2-1.8)	2.4 (1.1-3.6)	3.3 (1.8-4.7)	4.0 (2.4-5.5)	4.2 (2.5-5.8)	n.a.
CBH stem	RM Pressfit cup	551*	75 (69-79)	23	4	6	11	2	0	2.2 (1.0-3.4)	3.7 (2.1-5.3)	3.9 (2.3-5.5)	4.3 (2.6-6.0)	4.3 (2.6-6.0)	n.a.
Alloclassic Zweymuller SL	Trabecular Metal	547*	68 (62-75)	27	2	8	9	7	1	0.6 (0.0-1.2)	1.9 (0.7-3.0)	2.6 (1.3-4.0)	3.4 (1.8-4.9)	3.6 (2.0-5.2)	5.5 (3.3-7.6)

* Denotes prosthesis combinations with no reported use in primary THAs in 2022.
Please note: n.a. if <50 cases were at risk; THA: total hip arthroplasty; CI: confidence interval; IQR: interquartile range.

Only combinations with over 500 procedures have been listed.
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure, femoral head size and articulation of the prosthesis may have influenced the cumulative revision percentages.

Hip » Survival » Revision per component name » Cemented primary THA – major revision

TABLE Cumulative major revision percentages of the most frequently used cemented primary total hip arthroplasties by prosthesis component combination of patients who underwent a THA for osteoarthritis in the Netherlands in 2007-2022 (n=89,014)

					Cumulative revision percentage Kaplan Meier (95% CI)
Femur component	Acetabulum component	Total primary THAs (n)	Median (IQR) age (yr)	Major revision¹ arthroplasties (n)	1yr	3yr	5yr	7yr	10yr	14yr
All cemented THAs for osteoarthritis		89,014	76 (71-81)	1,944	0.7 (0.6-0.7)	1.4 (1.3-1.4)	1.8 (1.7-1.9)	2.3 (2.1-2.4)	2.9 (2.8-3.1)	3.8 (3.6-4.1)
Lubinus SPII	IP Cup	15,008	77 (72-81)	313	0.6 (0.4-0.7)	1.4 (1.2-1.6)	1.9 (1.7-2.2)	2.2 (2.0-2.5)	2.7 (2.3-3.0)	3.6 (3.0-4.2)
Original ME Muller	Muller low profile Durasul	9,450	75 (70-80)	113	0.5 (0.4-0.7)	1.0 (0.8-1.2)	1.3 (1.0-1.6)	1.4 (1.1-1.7)	1.8 (1.4-2.1)	2.0 (1.5-2.5)
Lubinus SPII	FAL Cup	6,450	75 (70-80)	150	0.9 (0.7-1.2)	1.6 (1.3-1.9)	2.2 (1.8-2.6)	2.9 (2.4-3.4)	3.6 (2.9-4.2)	4.4 (3.4-5.4)
Original ME Muller	Muller low profile	6,443	77 (73-81)	146	0.9 (0.7-1.1)	1.8 (1.4-2.1)	2.1 (1.7-2.4)	2.4 (2.0-2.8)	2.5 (2.1-2.9)	2.8 (2.3-3.3)
Exeter	Exeter Rimfit X3	5,098	76 (69-80)	80	0.7 (0.4-0.9)	1.2 (0.9-1.5)	1.7 (1.3-2.0)	1.8 (1.4-2.3)	2.4 (1.7-3.0)	n.a.
Spectron EF	Reflection All Poly XLPE	4,976	77 (73-82)	99	0.4 (0.2-0.5)	1.0 (0.7-1.3)	1.5 (1.1-1.8)	2.1 (1.6-2.5)	2.5 (2.0-2.9)	2.7 (2.1-3.2)
Stanmore	Stanmore	3,381	75 (70-80)	69	0.5 (0.3-0.8)	1.3 (0.9-1.7)	1.7 (1.2-2.1)	1.9 (1.4-2.3)	2.3 (1.7-2.8)	2.8 (2.0-3.7)
Exeter	Exeter Contemporary Hooded	2,827*	77 (72-81)	87	0.7 (0.4-1.0)	1.2 (0.8-1.6)	1.8 (1.3-2.3)	2.3 (1.8-2.9)	3.9 (3.0-4.7)	4.6 (3.5-5.8)
Lubinus SPII	SHP	2,506*	75 (71-80)	47	0.2 (0.0-0.4)	0.6 (0.3-0.9)	0.9 (0.5-1.3)	1.7 (1.1-2.2)	2.0 (1.4-2.6)	2.5 (1.6-3.4)
Exeter	Exeter	2,447*	73 (68-79)	123	1.8 (1.2-2.3)	2.5 (1.9-3.1)	3.1 (2.4-3.8)	3.9 (3.1-4.6)	5.2 (4.2-6.1)	6.0 (4.9-7.0)

¹ Revision of at least the acetabulum or femur component.
* Denotes prosthesis combinations with no reported use in primary THAs in 2022.
Please note: n.a. if <50 cases were at risk; THA: total hip arthroplasty; CI: confidence interval; IQR: interquartile range.

Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure, femoral head size and articulation of the prosthesis may have influenced the cumulative revision percentages.

Hip » Survival » Revision per component name » Uncemented primary THA – major revision

TABLE Cumulative major revision percentages of the most frequently used uncemented primary total hip arthroplasties by prosthesis component combination of patients who underwent a THA for osteoarthritis in the Netherlands in 2007-2022 (n=230,573)

					Cumulative revision percentage (95% CI)
Femur component	Acetabulum component	Total primary THAs (n)	Median (IQR) age (yr)	Major revision¹ arthroplasties (n)	1yr	3yr	5yr	7yr	10yr	14yr
All uncemented THAs for osteoarthritis		230,573	68 (62-74)	6,646	1.1 (1.0-1.1)	1.9 (1.9-2.0)	2.5 (2.4-2.5)	3.0 (2.9-3.1)	3.8 (3.7-3.9)	5.1 (4.9-5.2)
Corail	Pinnacle	41,174	69 (63-75)	701	0.7 (0.6-0.8)	1.3 (1.2-1.4)	1.7 (1.5-1.8)	1.9 (1.8-2.1)	2.6 (2.4-2.8)	3.1 (2.7-3.5)
Taperloc Complete	Allofit	24,355	67 (61-73)	362	1.0 (0.9-1.1)	1.6 (1.4-1.8)	2.0 (1.8-2.2)	2.1 (1.8-2.4)	n.a.	n.a.
Alloclassic Zweymuller SL	Allofit	14,806	70 (64-77)	438	0.9 (0.7-1.0)	1.6 (1.4-1.8)	2.1 (1.9-2.3)	2.5 (2.2-2.8)	3.5 (3.1-3.8)	4.4 (3.9-5.0)
Polarstem	R3	12,311	70 (63-75)	159	0.9 (0.8-1.1)	1.4 (1.1-1.6)	1.9 (1.5-2.2)	2.1 (1.5-2.6)	n.a.	n.a.
CLS Spotorno	Allofit	11,557	64 (58-69)	434	1.9 (1.7-2.2)	2.8 (2.5-3.1)	3.3 (3.0-3.6)	3.8 (3.4-4.1)	4.4 (4.0-4.8)	5.1 (4.3-5.8)
Taperloc Complete	Exceed ABT	8,825	69 (63-75)	157	1.1 (0.9-1.3)	1.5 (1.2-1.7)	1.7 (1.4-1.9)	2.0 (1.6-2.3)	2.3 (1.9-2.7)	n.a.
Accolade	Trident	7,605	69 (62-76)	285	1.0 (0.8-1.3)	2.2 (1.9-2.6)	3.0 (2.6-3.4)	3.7 (3.2-4.1)	4.6 (4.0-5.2)	7.5 (5.4-9.6)
Mallory Head Stems	Mallory Head	6,019	65 (60-69)	167	0.9 (0.7-1.2)	1.6 (1.3-1.9)	2.0 (1.6-2.4)	2.4 (2.0-2.8)	2.8 (2.3-3.2)	3.5 (2.8-4.1)
Accolade II	Trident	5,021	69 (62-75)	64	1.1 (0.8-1.4)	1.5 (1.1-1.9)	1.8 (1.1-2.5)	3.5 (0.1-6.9)	n.a.	n.a.
Twinsys stem Cementless	RM Pressfit Vitamys cup	4,888	66 (60-72)	124	1.4 (1.1-1.8)	2.1 (1.6-2.5)	2.4 (1.9-2.8)	2.8 (2.3-3.3)	4.3 (3.3-5.3)	n.a.

¹ Revision of at least the acetabulum or femur component.
Please note: n.a. if <50 cases were at risk; THA: total hip arthroplasty; CI: confidence interval; IQR: interquartile range.

Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure, femoral head size and articulation of the prosthesis may have influenced the cumulative revision percentages.

Hip » Survival » Revision per component name » Bone cement THA

TABLE Cumulative revision percentages of the most frequently types of bone cement by type of mixing system in primary total hip arthroplasties in the Netherlands in 2007-2022

			Cumulative revision percentage Kaplan Meier (95% CI)
Bone cement	Total primary THAs (n)	Total RAs (n)	1yr	3yr	5yr	7yr	10yr	14yr
Separately packed	95,252	3,388	1.5 (1.4-1.5)	2.4 (2.3-2.5)	3.0 (2.9-3.1)	3.5 (3.4-3.6)	4.4 (4.2-4.5)	5.6 (5.3-5.9)
Palacos R+G	73,479	2,516	1.5 (1.4-1.6)	2.5 (2.4-2.6)	3.1 (2.9-3.2)	3.5 (3.4-3.6)	4.2 (4.1-4.4)	5.3 (5.0-5.6)
Refobacin Bone Cement R	6,387	194	1.0 (0.8-1.3)	1.9 (1.5-2.2)	2.3 (1.9-2.6)	2.8 (2.4-3.3)	3.7 (3.1-4.2)	4.0 (3.4-4.6)
Palacos MV+G	3,916	106	0.9 (0.6-1.2)	1.5 (1.1-1.9)	2.2 (1.7-2.7)	3.2 (2.6-3.8)	3.6 (2.9-4.4)	n.a.
Simplex ABC EC	2,685	158	2.2 (1.7-2.8)	3.5 (2.8-4.2)	4.4 (3.6-5.2)	5.1 (4.2-6.0)	6.6 (5.5-7.8)	10.4 (7.9-13.0)
Simplex ABC Tobra	2,341	155	2.0 (1.4-2.5)	3.2 (2.5-4.0)	4.0 (3.2-4.8)	4.7 (3.8-5.6)	6.6 (5.5-7.6)	8.6 (7.1-10.2)
Simplex P	1,323*	30	0.8 (0.3-1.2)	1.8 (1.1-2.5)	1.9 (1.1-2.6)	2.1 (1.3-2.8)	2.8 (1.7-3.8)	2.8 (1.7-3.8)
Simplex HV	574*	13	0.7 (0.0-1.4)	0.9 (0.1-1.7)	2.1 (0.9-3.3)	2.6 (1.2-4.0)	n.a.	n.a.
Refobacin Plus Bone Cement	561*	26	1.8 (0.7-2.9)	2.9 (1.5-4.3)	3.7 (2.1-5.3)	4.1 (2.4-5.8)	4.8 (2.9-6.7)	5.7 (3.4-8.0)
Palamed G	493*	15	0.4 (0.0-1.0)	0.8 (0.0-1.6)	1.3 (0.3-2.3)	2.0 (0.7-3.2)	3.0 (1.4-4.6)	4.0 (1.8-6.1)
Biomet Plus Bone Cement	453*	26	0.4 (0.0-1.1)	1.4 (0.3-2.4)	2.5 (1.1-4.0)	3.3 (1.6-5.0)	4.4 (2.4-6.3)	7.1 (4.4-9.7)
Subiton G	434	8	1.2 (0.2-2.2)	2.2 (0.6-3.7)	n.a.	n.a.	n.a.	n.a.
CMW 1 Gentamicin Bone Cement	327*	14	1.8 (0.4-3.3)	2.8 (1.0-4.6)	3.1 (1.2-5.0)	3.1 (1.2-5.0)	4.0 (1.8-6.2)	4.9 (2.4-7.5)
Palacos R	312*	17	1.6 (0.2-3.0)	2.7 (0.8-4.5)	4.2 (1.8-6.5)	5.0 (2.4-7.6)	6.8 (3.5-10.0)	n.a.
Palamed	277*	26	1.1 (0.0-2.3)	2.5 (0.7-4.4)	3.7 (1.4-5.9)	3.7 (1.4-5.9)	6.1 (3.2-9.0)	10.6 (6.7-14.5)
Pre-packed in a vacuum mixing system	38,541	1,101	2.0 (1.8-2.1)	2.7 (2.6-2.9)	3.3 (3.1-3.5)	3.8 (3.5-4.0)	4.5 (4.1-4.8)	4.8 (4.3-5.4)
Refobacin Bone Cement R	18,013	558	2.1 (1.8-2.3)	2.8 (2.6-3.1)	3.4 (3.1-3.7)	3.9 (3.6-4.3)	4.8 (4.2-5.4)	n.a.
Palacos R+G	15,065	390	2.0 (1.8-2.3)	2.8 (2.5-3.1)	3.4 (3.0-3.8)	3.7 (3.2-4.2)	n.a.	n.a.
Refobacin Plus Bone Cement	4,701	128	1.3 (0.9-1.6)	2.2 (1.7-2.6)	2.6 (2.1-3.1)	3.1 (2.5-3.6)	3.5 (2.8-4.2)	n.a.
Cemex Genta	432	10	1.2 (0.2-2.2)	1.9 (0.6-3.2)	2.2 (0.8-3.5)	2.2 (0.8-3.5)	3.3 (0.7-6.0)	n.a.

* Denotes types of bone cement with no reported use in primary THAs in 2022.
Please note: n.a. if <50 cases were at risk; THA: total hip arthroplasty; RA: revision arthroplasty; CI: confidence interval; IQR: interquartile range.

Only types of bone cement with over 250 procedures have been listed.
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure, femoral head size and articulation of the prosthesis may have influenced the cumulative revision percentages.

This website is only accessable on large screens